AI Article Synopsis
- The last decade has seen a huge investment in Drug Discovery due to advancements in understanding the human genome and new high-throughput technologies.
- Despite this investment, there has been a decrease in the number of new drugs introduced to the market.
- The Society for Medicines Research (SMR) held a meeting titled "Addressing the Innovation Gap" to discuss the challenges in the pharmaceutical industry and potential strategies for future success.*
Article Abstract
The 10 years since the mid-1990s have witnessed an unprecedented investment in Drug Discovery driven by both the unraveling of the human genome and the parallel introduction of various high-throughput technologies. During the same period, industry metrics describe a decline in the numbers of new molecular entities launched upon the global pharmaceutical markets. The Society for Medicines Research (SMR) meeting entitled "Addressing the Innovation Gap" brought together a program of expert speakers to comment upon the challenges currently facing the pharmaceutical industry and some of the measures being undertaken to enable future success.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!